Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- CRF-2? -2? Spea 1 central nervous system
- Product Overview:
Urocortin III is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF (Item No. 24407), urocortin (Item No. 24745), urocortin II (Item No. 24746), frog sauvagine, and piscine urotensin I.{39576} Mouse urocortin III shares 90, 40, 37, and 18% identity to human urocortin III (Item No. 24748), mouse urocortin II (Item No. 24747), human urocortin (Item No. 24744), and mouse urocortin, respectively. It is expressed in the hypothalamus, brainstem, lateral septum (LS)/bed nucleus of stria terminalis (BnST) in the CNS and the small intestine, pancreatic ?-cells, and skin in the periphery in mice. Urocortin III selectively binds to type 2 CRF receptors (Kis = 5, 1.8, and >100 nM for rat CRF2?, rat CRF2?, and human CRF1, respectively). It stimulates cAMP production in CHO cells expressing rat CRF2? and mouse CRF2? (EC50s = 0.073 and 0.08 nM, respectively) as well as in cultured anterior pituitary cells expressing endogenous CRF2?. In vivo, urocortin III (2 ?g, i.p.) accelerates metamorphosis of S. hammondii tadpoles.{39577} Urocortin III (20 ?g, i.c.v.) increases exploration in the open field test and decreases latency to enter the lit compartment in the dark-light emergence test in mice, indicating anxiolytic-like activity, and mRNA expression is increased in mouse brain in response to restraint.{24749} It is co-released with insulin to potentiate glucose-stimulated somatostatin release in vitro and in vivo in wild-type mice, however, it is depleted from ?-cells in mouse and macaque models of type 2 diabetes, suggesting a role in glycemic control.{39579}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.